ESCMID: HIV treatment reduces accelerated biological aging by nearly four years, landmark study shows

Back to the "HIV and Co-Infections News" list

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) news release

A major study presented at ESCMID Global 2026 has found that antiretroviral therapy (ART) reduces accelerated biological aging in people with HIV by nearly four years, a finding that could transform how clinicians monitor HIV treatment and long-term health outcomes.

Researchers developed a plasma proteomic aging clock — a tool that estimates biological age, reflecting physiological aging rather than chronological age — using patterns across hundreds of blood proteins. The model was applied to participants in the Swiss HIV Cohort Study.

“This research demonstrates the importance of early start and optimal adherence to ART,” commented lead study author Dr. Barry Ryan, a postdoctoral researcher at EPFL, Switzerland.

Read the full news release here.

 

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.